-
公开(公告)号：US09764028B2
公开(公告)日：2017-09-19
申请号：US15248850
申请日：2016-08-26
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
IPC: C07K14/34 , C07K14/005 , A61K39/29 , C12N15/62 , A61K39/39 , C12N9/10 , A61K39/12 , A61K39/05 , C12N7/00 , A61K38/00 , A61K39/00
CPC classification number: A61K39/39 , A61K38/00 , A61K39/05 , A61K39/12 , A61K39/29 , A61K2039/55505 , A61K2039/55516 , A61K2039/55544 , A61K2039/6037 , C07K14/005 , C07K14/34 , C07K2319/03 , C07K2319/55 , C07K2319/74 , C12N7/00 , C12N9/1048 , C12N15/62 , C12N2760/16122 , C12N2760/16134 , C12N2770/28122 , C12N2770/28134
Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
-
公开(公告)号：US11427618B2
公开(公告)日：2022-08-30
申请号：US15734715
申请日：2019-06-04
Applicant: Xiamen University , Xiamen Innovax Biotech Co., Ltd.
Inventor： Shaowei Li , Daning Wang , Zhiping Wang , Xinlin Liu , Jun Zhang , Ningshao Xia
IPC: C07K14/025 , A61K39/12 , C12N7/00 , C12N15/70 , A61K39/00
Abstract: The invention relates to a mutated HPV39 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV39 and HPV68, or HPV39, HPV68 and HPV70), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
-
3.发明申请Fusion Protein Comprising Diphtheria Toxin Non-Toxic Mutant CRM197 or Fragment Thereof 有权包含白喉毒素非毒性突变体CRM197或其片段的融合蛋白
公开(公告)号：US20170015713A1
公开(公告)日：2017-01-19
申请号：US15248850
申请日：2016-08-26
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
IPC: C07K14/34 , C12N15/62 , A61K39/29 , C07K14/005 , A61K39/39
CPC classification number: A61K39/39 , A61K38/00 , A61K39/05 , A61K39/12 , A61K39/29 , A61K2039/55505 , A61K2039/55516 , A61K2039/55544 , A61K2039/6037 , C07K14/005 , C07K14/34 , C07K2319/03 , C07K2319/55 , C07K2319/74 , C12N7/00 , C12N9/1048 , C12N15/62 , C12N2760/16122 , C12N2760/16134 , C12N2770/28122 , C12N2770/28134
Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
Abstract translation: 在本发明中提供了作为融合蛋白中的佐剂的白喉毒素无毒突变体CRM197或其片段，以及用于增强与其融合的靶蛋白的免疫原性的用途，例如HEV衣壳蛋白或 流感病毒M2蛋白或其免疫原性片段。 还提供了增强靶蛋白的免疫原性的方法，其包括将CRM197或其片段与靶蛋白的融合表达形成融合蛋白。 还提供了包含CRM197或其片段和靶蛋白的融合蛋白，CRM197或其片段增强靶蛋白的免疫原性。 本发明还提供编码融合蛋白的分离的核酸，包含所述核酸的构建体和载体，以及包含所述核酸的宿主细胞。
-
公开(公告)号：US20160200776A1
公开(公告)日：2016-07-14
申请号：US15057416
申请日：2016-03-01
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Minxi Wei , Xianglin Kong , Yingbin Wang , Jun Zhang , Ningshao Xia
IPC: C07K14/005 , A61K39/12 , C12N7/00
CPC classification number: C07K14/005 , A61K38/00 , A61K39/12 , A61K2039/5258 , A61K2039/585 , C12N7/00 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034
Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
Abstract translation: 提供人类乳头瘤病毒58型的N-末端截短的L1蛋白，其编码序列及其制备方法和包含该蛋白质的病毒样颗粒。 进一步提供蛋白质和病毒样颗粒在制备药物组合物或疫苗中的用途。 药物组合物或疫苗用于预防HPV感染和HPV感染引起的疾病。
-
公开(公告)号：US12097251B2
公开(公告)日：2024-09-24
申请号：US17280805
申请日：2019-09-26
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Daning Wang , Jie Chen , Ying Gu , Jun Zhang , Ningshao Xia
IPC: A61K39/12 , A61P31/20 , C07K14/015 , C12N7/00
CPC classification number: A61K39/12 , A61P31/20 , C07K14/015 , C12N7/00
Abstract: Provided are a mutated HPV51 L1 protein or a variant thereof, a coding sequence thereof, a preparation method therefor, and a virus-like particle containing same, wherein the protein or the variant and the virus-like particle thereof are capable of inducing neutralizing antibodies against at least two types of HPV (for example, HPV51 and HPV69, or HPV51, HPV69 and HPV26). Also provided is the use of the above-mentioned protein and the virus-like particle for preparing a pharmaceutical composition or a vaccine, wherein the pharmaceutical composition or the vaccine can be used to prevent infections of the at least two types of HPV and diseases caused by the infections, such as cervical cancer and condyloma acuminatum.
-
公开(公告)号：US11771754B2
公开(公告)日：2023-10-03
申请号：US15734670
申请日：2019-06-04
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Shuo Song , Maozhou He , Jingjie Shi , Ying Gu , Ningshao Xia
IPC: A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
CPC classification number: A61K39/12 , C12N7/00 , A61K2039/53 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034 , C12N2710/20071
Abstract: The present invention relates to a mutated HPV18 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (for example, HPV18 and HPV45, or HPV18, HPV45 and HPV59), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
-
公开(公告)号：US09757450B2
公开(公告)日：2017-09-12
申请号：US15248779
申请日：2016-08-26
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Cuiling Song , Chunyan Yang , Ying Gu , Wenxin Luo , Ningshao Xia
IPC: A61K39/00 , A61K39/39 , C12N15/62 , C07K14/005 , C12N9/10 , A61K39/12 , A61K39/05 , C12N7/00 , A61K39/29 , C07K14/34 , A61K38/00
CPC classification number: A61K39/39 , A61K38/00 , A61K39/05 , A61K39/12 , A61K39/29 , A61K2039/55505 , A61K2039/55516 , A61K2039/55544 , A61K2039/6037 , C07K14/005 , C07K14/34 , C07K2319/03 , C07K2319/55 , C07K2319/74 , C12N7/00 , C12N9/1048 , C12N15/62 , C12N2760/16122 , C12N2760/16134 , C12N2770/28122 , C12N2770/28134
Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.
-
公开(公告)号：US11464846B2
公开(公告)日：2022-10-11
申请号：US15734750
申请日：2019-06-04
Applicant: Xiamen University , Xiamen Innovax Biotech Co., Ltd.
Inventor： Shaowei Li , Xinlin Liu , Yurou Yang , Jie Chen , Daning Wang , Ningshao Xia
IPC: A61K39/12 , C07K14/025 , C12N7/00 , A61K39/00
Abstract: The invention relates to a mutated HPV66 L1 protein (or a variant thereof), a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein (or a variant thereof) and the virus-like particle can induce the generation of neutralizing antibodies against at least two HPV types (e.g. HPV66 and HPV56, or HPV66, HPV56 and HPV53), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. The invention further relates to the use of the protein and the virus-like particle in the manufacture of a pharmaceutical composition or a vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
-
公开(公告)号：US09738691B2
公开(公告)日：2017-08-22
申请号：US15057416
申请日：2016-03-01
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Shaowei Li , Minxi Wei , Xianglin Kong , Yingbin Wang , Jun Zhang , Ningshao Xia
IPC: A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00 , A61K38/00
CPC classification number: C07K14/005 , A61K38/00 , A61K39/12 , A61K2039/5258 , A61K2039/585 , C12N7/00 , C12N2710/20022 , C12N2710/20023 , C12N2710/20034
Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.
-
公开(公告)号：US11213580B2
公开(公告)日：2022-01-04
申请号：US16630673
申请日：2018-07-13
Applicant: XIAMEN UNIVERSITY , XIAMEN INNOVAX BIOTECH CO., LTD.
Inventor： Ying Gu , Shaowei Li , Shuo Song , Maozhou He , Zhihai Li , Ningshao Xia
IPC: A61K39/00 , A61K39/12 , C07K14/005 , C07K14/025 , C12N7/00 , A61P31/20 , A61K39/39
Abstract: Provided are a mutated HPV16 L1 protein (or a variant thereof), a sequence encoding the same and a method for preparing the same, as well as a virus-like particle comprising the same. The protein (or variant thereof) and the virus-like particle are capable of inducing neutralizing antibodies against at least two types of HPV (e.g., HPV16 and HPV35, or HPV16, HPV35, and HPV31), and therefore can be used to prevent infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum. Also provided are a use of the above protein and virus-like particle in the manufacture of a pharmaceutical composition or vaccine for preventing infection by said at least two HPV types, and a disease caused by said infection, such as cervical cancer and condyloma acuminatum.
